대장암 치료제 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of colorectal cancer therapeutics Market

The global colorectal cancer therapeutics market was valued at USD 14.41 billion in 2025 and is projected to grow from USD 15.26 billion in 2026 to USD 24.10 billion by 2034, registering a CAGR of 5.88% from 2026 to 2034. The market is being driven by the increasing prevalence of colorectal cancer, rising awareness, improved diagnostic capabilities, and continuous development of innovative oncology therapies. North America dominated the market with a 44.60% share in 2025.

Colorectal cancer includes major disease forms such as colorectal adenocarcinoma and gastrointestinal carcinoid tumors. Increasing diagnosis rates and the need for effective treatments are encouraging pharmaceutical companies to expand their oncology pipelines and introduce advanced therapeutics.

Market Size and Forecast

Year Market Size

2025 USD 14.41 Billion

2026 USD 15.26 Billion

2034 USD 24.10 Billion

Colorectal Cancer Therapeutics Market Trends

The colorectal cancer therapeutics market trends are increasingly influenced by targeted therapies, immunotherapies, advanced diagnostics, and personalized treatment approaches. Greater awareness of colorectal cancer symptoms and risk factors is supporting earlier diagnosis. Pharmaceutical companies are also increasing R&D investments to develop therapies that address unmet treatment needs and improve patient outcomes.

Market Drivers

Increasing Awareness and Drug Innovation

Growing awareness about colorectal cancer and the importance of early diagnosis is supporting demand for therapeutics. The introduction of innovative drugs and combination treatment approaches is strengthening the market. Targeted therapies have become particularly important because they provide more specialized treatment options for eligible patients.

Rising Disease Prevalence and Unmet Treatment Needs

The increasing prevalence of colorectal cancer and its associated mortality is creating substantial demand for effective treatments. Continuous clinical research, novel product launches, and development of advanced therapies are helping address unmet medical needs across different patient populations.

Market Restraints and Challenges

High treatment costs and the increasing availability of lower-priced generic medicines can limit market expansion in certain therapy categories. Chemotherapy, in particular, faces competitive pressure from generics. Additionally, advanced therapeutics require extensive clinical research, regulatory approvals, and significant investment, which can increase development costs and commercialization risks.

Market Opportunities

The growing adoption of targeted therapy, immunotherapy, personalized medicine, and combination treatments offers significant market opportunities. Increasing healthcare expenditure and improving oncology infrastructure in emerging economies can further expand access to colorectal cancer treatments. Online pharmacy adoption is another emerging opportunity because of its convenience and expanding digital healthcare ecosystem.

Segmentation Analysis

By Therapy

The market is segmented into Targeted Therapy, Immunotherapy, Chemotherapy, and Others. Targeted therapy held the leading position and reached USD 9.85 billion in 2025, supported by therapies such as Avastin, Erbitux, and Stivarga. Immunotherapy and chemotherapy also remain important treatment categories.

By Cancer Type

The market includes Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others. Colorectal adenocarcinoma is expected to experience significant growth due to its large share of colorectal cancer cases and the treatment requirements associated with aggressive disease forms.

By Distribution Channel

The market is divided into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Hospital pharmacies dominated with a 49.30% share in 2025, as many colorectal cancer medicines require specialist diagnosis and administration. Online pharmacies are expected to experience strong growth due to convenience and accessibility.

Regional Analysis

North America was the leading regional market in 2025, accounting for 44.60% of the global market. Strong clinical research, advanced diagnostics, product launches, and high treatment adoption support regional growth.

Asia Pacific is expected to witness strong growth because of rising cancer prevalence, improving healthcare infrastructure, increasing disposable income, and greater awareness. Japan's market reached USD 1.03 billion in 2025, while China is expected to register strong growth.

Europe is projected to experience considerable growth, supported by high disease prevalence and increasing adoption of advanced therapies. The U.K., France, and Spain are among the important markets.

Latin America is expected to grow steadily, while the Middle East and Africa are projected to show comparatively limited growth initially but increasing potential over the longer term.

Key Industry Players

Major companies include Genentech, Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Sanofi, Merck Sharp & Dohme Corp., Taiho Pharmaceutical, Bayer AG, Regeneron Pharmaceuticals, Novartis AG, and Ipsen Biopharmaceuticals.

Recent Industry Developments

In December 2024, the European Commission approved the combination of Opdivo and Yervoy as a first-line treatment for certain MSI-H or dMMR metastatic colorectal cancer patients.

In February 2024, KRAZATI received U.S. FDA accelerated approval in combination with cetuximab for previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer.

Investment Analysis and Opportunities

Investment opportunities are expanding across targeted therapies, immunotherapies, personalized medicine, companion diagnostics, and novel combination treatments. Companies with strong oncology pipelines, advanced clinical research capabilities, and innovative drug-development strategies are positioned to benefit from the evolving colorectal cancer therapeutics landscape.

Conclusion

The global colorectal cancer therapeutics market is expected to maintain steady expansion due to rising disease prevalence, growing awareness, improved diagnosis, and continuous pharmaceutical innovation. The market is valued at USD 14.41 billion in 2025, projected to reach USD 15.26 billion in 2026, and is expected to reach USD 24.10 billion by 2034. Targeted therapy, advanced immunotherapy, personalized treatment, and growing healthcare investment will remain key factors shaping the colorectal cancer therapeutics market outlook through 2034.

Unit Value (USD billion)

Segmentation By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Others

By Cancer Type

• Colorectal Adenocarcinoma
• Gastrointestinal Carcinoid Tumors
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Colorectal Cancer - By Key Countries, 2025
• 4.2. Pipeline Analysis, Key Players
• 4.3. Key Industry Developments
• 4.4. New Product Launches
• 4.5. Increasing R&D Initiatives in Colorectal Cancer Diagnostics

5. Global Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Therapy
  • 5.2.1. Targeted Therapy
  • 5.2.2. Immunotherapy
  • 5.2.3. Chemotherapy
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Cancer Type
  • 5.3.1. Colorectal Adenocarcinoma
  • 5.3.2. Gastrointestinal Carcinoid Tumors
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Therapy
  • 6.2.1. Targeted Therapy
  • 6.2.2. Immunotherapy
  • 6.2.3. Chemotherapy
  • 6.2.4. Others
• 6.3. Market Analysis - By Cancer Type
  • 6.3.1. Colorectal Adenocarcinoma
  • 6.3.2. Gastrointestinal Carcinoid Tumors
  • 6.3.3. Others
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Pharmacies
  • 6.4.4. Others
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Therapy
  • 7.2.1. Targeted Therapy
  • 7.2.2. Immunotherapy
  • 7.2.3. Chemotherapy
  • 7.2.4. Others
• 7.3. Market Analysis - By Cancer Type
  • 7.3.1. Colorectal Adenocarcinoma
  • 7.3.2. Gastrointestinal Carcinoid Tumors
  • 7.3.3. Others
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies
  • 7.4.4. Others
• 7.5. Market Analysis - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Therapy
  • 8.2.1. Targeted Therapy
  • 8.2.2. Immunotherapy
  • 8.2.3. Chemotherapy
  • 8.2.4. Others
• 8.3. Market Analysis - By Cancer Type
  • 8.3.1. Colorectal Adenocarcinoma
  • 8.3.2. Gastrointestinal Carcinoid Tumors
  • 8.3.3. Others
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies
  • 8.4.4. Others
• 8.5. Market Analysis - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Therapy
  • 9.2.1. Targeted Therapy
  • 9.2.2. Immunotherapy
  • 9.2.3. Chemotherapy
  • 9.2.4. Others
• 9.3. Market Analysis - By Cancer Type
  • 9.3.1. Colorectal Adenocarcinoma
  • 9.3.2. Gastrointestinal Carcinoid Tumors
  • 9.3.3. Others
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
  • 9.4.4. Others
• 9.5. Market Analysis - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Therapy
  • 10.2.1. Targeted Therapy
  • 10.2.2. Immunotherapy
  • 10.2.3. Chemotherapy
  • 10.2.4. Others
• 10.3. Market Analysis - By Cancer Type
  • 10.3.1. Colorectal Adenocarcinoma
  • 10.3.2. Gastrointestinal Carcinoid Tumors
  • 10.3.3. Others
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
  • 10.4.4. Others
• 10.5. Market Analysis - By Country/ Sub-Region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Genentech, Inc.
    • 11.5.1.1. Overview
    • 11.5.1.2. Products & Services
    • 11.5.1.3. SWOT Analysis
    • 11.5.1.4. Recent Developments
    • 11.5.1.5. Strategies
    • 11.5.1.6. Financials
  • 11.5.2. Eli Lilly and Company
    • 11.5.2.1. Overview
    • 11.5.2.2. Products & Services
    • 11.5.2.3. SWOT Analysis
    • 11.5.2.4. Recent Developments
    • 11.5.2.5. Strategies
    • 11.5.2.6. Financials
  • 11.5.3. Pfizer Inc.
    • 11.5.3.1. Overview
    • 11.5.3.2. Products & Services
    • 11.5.3.3. SWOT Analysis
    • 11.5.3.4. Recent Developments
    • 11.5.3.5. Strategies
    • 11.5.3.6. Financials
  • 11.5.4. Sanofi
    • 11.5.4.1. Overview
    • 11.5.4.2. Products & Services
    • 11.5.4.3. SWOT Analysis
    • 11.5.4.4. Recent Developments
    • 11.5.4.5. Strategies
    • 11.5.4.6. Financials
  • 11.5.5. Teva Pharmaceutical Industries Ltd.
    • 11.5.5.1. Overview
    • 11.5.5.2. Products & Services
    • 11.5.5.3. SWOT Analysis
    • 11.5.5.4. Recent Developments
    • 11.5.5.5. Strategies
    • 11.5.5.6. Financials
  • 11.5.6. Bristol Myers Squibb
    • 11.5.6.1. Overview
    • 11.5.6.2. Products & Services
    • 11.5.6.3. SWOT Analysis
    • 11.5.6.4. Recent Developments
    • 11.5.6.5. Strategies
    • 11.5.6.6. Financials
  • 11.5.7. Merck Sharp & Dohme Corp.
    • 11.5.7.1. Overview
    • 11.5.7.2. Products & Services
    • 11.5.7.3. SWOT Analysis
    • 11.5.7.4. Recent Developments
    • 11.5.7.5. Strategies
    • 11.5.7.6. Financials
  • 11.5.8. Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
    • 11.5.8.1. Overview
    • 11.5.8.2. Products & Services
    • 11.5.8.3. SWOT Analysis
    • 11.5.8.4. Recent Developments
    • 11.5.8.5. Strategies
    • 11.5.8.6. Financials
  • 11.5.9. Bayer AG
    • 11.5.9.1. Overview
    • 11.5.9.2. Products & Services
    • 11.5.9.3. SWOT Analysis
    • 11.5.9.4. Recent Developments
    • 11.5.9.5. Strategies
    • 11.5.9.6. Financials
  • 11.5.10. Regeneron Pharmaceuticals, Inc.
    • 11.5.10.1. Overview
    • 11.5.10.2. Products & Services
    • 11.5.10.3. SWOT Analysis
    • 11.5.10.4. Recent Developments
    • 11.5.10.5. Strategies
    • 11.5.10.6. Financials
  • 11.5.11. Novartis AG
    • 11.5.11.1. Overview
    • 11.5.11.2. Products & Services
    • 11.5.11.3. SWOT Analysis
    • 11.5.11.4. Recent Developments
    • 11.5.11.5. Strategies
    • 11.5.11.6. Financials
  • 11.5.12. Ipsen Biopharmaceuticals, Inc.
    • 11.5.12.1. Overview
    • 11.5.12.2. Products & Services
    • 11.5.12.3. SWOT Analysis
    • 11.5.12.4. Recent Developments
    • 11.5.12.5. Strategies
    • 11.5.12.6. Financials

12. Appendix